Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

NCT06874751 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06874751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06874751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
December 6, 2024
Completion date
March 28, 2025
Enrollment
45,456 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease (ascvd), obesity, overweight